The drug manufacturers, fiercely opposed to the bill on the financing of Social Security (PLFSS), again called on the government on Thursday to review its copy, highlighting an increased risk of supply disruptions.
What is happening is extremely serious; the investments that will no longer be made will have a short, medium and long-term impact, hence our total alignment today between laboratories, hammered Audrey Derveloy, the president of Sanofi France, during a press conference organized by Leem, the federation of pharmaceutical companies.
For the occasion, a rare thing, many heads of laboratories, small and large, expressed themselves, regretting a reversal of the announcements made by President Macron, who had launched in 2021 an investment plan in the health of several Billions of Euro’s.
While at the height of the pandemic, relations between the pharmaceutical sector and the state seemed to be in good shape, the PLFSS 2023 changed the situation. The outstretched hand of the government, which has since modified certain elements of the bill, was not enough to reassure the industrialists, against the backdrop of a war of figures.
Risks stronger than savings
The PLFSS predicts that in 2023, 1.1 billion savings will have to be made on the reimbursement of drugs. It would be 3 billion euros disputes the Leem, an amount not sufficient to finance access to innovations, he says.
More broadly, manufacturers are demanding that the amount spent on drugs be revised upwards, in a context of inflation which particularly affects generic manufacturers.
Find the lowest rate for your real estate project!
The sector is also calling for the withdrawal of Article 30, which provides for the establishment of a drug listing mechanism, with non-listed drugs losing their reimbursement.
The Minister Delegate for Industry Roland Lescure recently announced that this procedure would be transformed into a simple experiment. Even on an experimental basis, such a measure is unacceptable, reacted the president for France of the giant of the generic Teva Jean-Louis Anspach.
The resulting risks are far greater than the savings that this system could generate, he estimated, judging that it would lead to a scarcity of the supply of drugs, and possible supply disruptions.